In the February 12, 2013, version of the Health and Human Services (HHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, the Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patient include raltegravir (RAL) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as the preferred integrase strand transfer inhibitor (INSTI)-based regimen, and elvitegravir (EVG)/cobicistat (cobi)/TDF/FTC as an alternative regimen for patients with estimated creatinine clearance (CrCl) ≥70 mL/min. Since the release of the Guidelines, a new INSTI, dolutegravir (DTG), was approved for use in ART-naive and ART-experienced patients. Additionally, long-term follow-up data (up to 144 weeks) from randomized clinical trials have demonstrated the durable safety and efficacy of EVG/cobi/TDF/FTC.
On the basis of these new findings, the Panel now recommends the following 4 INSTI-based regimens as preferred regimens for ART-naive patients (arranged in order of drug approval):
To access full article, please click here.
On 30th October 2013, Medecin Sans Frontieres launched a variety of new reports and advocacy tools at the Union Conference, including the DR-TB Drugs Under the Microscope, 3rd Edition report, and the "Test Me, Treat Me" TB Manifesto. You can find the press release by clicking here.
The DR-TB Drugs Under the Microscope report aims to provide information on the prices, sources, access environment and R&D landscape for DR-TB medicines. It includes an analysis of the progress being made globally for the development of life-saving medicines for TB patients as well as the many remaining challenges. The report is available for download on our website, here.
In addition, MSF has launched the next stage of the “Test me, treat me” DR-TB Manifesto. The Manifesto aims to raise the alarm about the devastating toll this disease is taking on patients, families and communities across the globe. The manifesto calls for greater government support for the diagnosis and treatment of this disease, better treatment regimens and more widely available and reliable diagnostic techniques. Please visit the new website, sign the manifesto and share widely (including hashtag #TBmanifesto if you use twitter).
MSF is participating throughout the Union Conference on Lung Health. To find out more about MSF activities between October 30 and November 4, please visit the website, www.msfaccess.org/content/TBUnion2013.
The U.S. Food and Drug Administration today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Approved for use as an aid in the diagnosis of HIV-1 and HIV-2 infection, the Alere Determine HIV-1/2 Ag/Ab Combo test is also the first FDA-approved test that independently distinguishes results for HIV-1 p24 antigen and HIV antibodies in a single test.
Read full press release by clicking here.
Definate Nhamo, Young Investigator for Project SHAZ!, a project led by Pangaea in partnership with the Zimbabwe AIDS Prevention Project (ZAPP), has been awarded the Women, Girls and HIV Investigators’ Prize at the International AIDS Conference in Kuala Lumpur for its research on the factors associated with gender-based violence and unintended pregnancy among adolescent women living with HIV in Zimbabwe. The Young Investigator Prize: Women, Girls and HIV/AIDS began in 2008 to support young woman investigator from a resource-limited setting whose abstract most demonstrates excellence in research and/or practice that address women, girls and gender issues related to HIV/AIDS. Its purpose is to encourage research in low- or middle-income countries that can benefit women and girls affected by HIV and AIDS. Pangaea Global AIDS Foundation is honored to be collaborating and will continue to collaborate with its partners in Zimbabwe in addressing young women health issues and empowerment. The winning abstract will be presented on Monday, July 1st, 12:30pm-2:30pm , Exhibition Hall, Ground Level.
During the conference, the World Health Organization (WHO) will be announcing its revised Consolidated HIV Guidelines. Pangaea Global AIDS Foundation contributed to the development of the revised guidelines by co-convening meetings addressing HIV Treatment Optimization as part of the Treatment 2.0 initiative, an international initiative launched by the WHO and UNAIDS that calls for the further scale-up of ART access based on most current information and available resources. These meetings provided input to WHO that was considered in the Guidelines’ development.
Over the last two years, Pangaea Global AIDS Foundation provided support to WHO and to UNAIDS in convening, moderating and reporting on a set of experts meetings to address drug regimens optimization, diagnostics monitoring and health services delivery. The meetings were held in Geneva, London, Harare, and Bangkok. Each meeting brought together experts in the field including community-based advocates and providers. The recommendations and outcomes of those meetings are available on the WHO website. Details on HIV Treatment Optimization activities are available at www.hivtreatmentoptimization.org
Pangaea will also be involved in the following set of activities during the conference:
Tuesday, 2 July 2013
6:30 – 8:30pm – Room TBA
3rd Annual Decade of Diagnostics Satellite – 2013 Update: Strategic Development of DC4 and Viral Load Testing: How will implementers and markets respond to new WHO Guidelines?
In this satellite session co-hosted by WHO, UNITAID and Pangaea Global AIDS Foundation, WHO will provide a high level strategic framework on implementation of WHO guidelines for CD4 and viral load monitoring, Implementers from South Africa and Kenya will discuss their national strategic plans to scale up CD4 and viral load monitoring as recommended by WHO, including challenges and implications of the new guidelines. The London School of Hygiene and Tropical Medicine will discuss progress made towards the harmonization of the regulation process for diagnostics to ensure faster access to safe, effective and cheaper products and UNITAID will discuss how the new Guidelines might impact the size and structure of diagnostics markets and mechanisms to ensure these markets are shaped to meet global public health goals. The Clinton Health Access Initiative and Médecins Sans Frontières will discuss how they will respond to new WHO Guidelines in their UNITAID-funded projects that span ten African countries.
Craig McClure, Chief of HIV/AIDS, UNICEF
Ilesh Jani, Director General, National Institute of Health, Mozambique
Nathan Ford, HIV/AIDS Dept, WHO
Wendy Stevens, Director, Clinical Laboratory Services, South Africa
Matilu Mwua, Director, Center of Infectious and Parasitic Disease Control, Kenya
Brenda Waning, Coordinator of Market Dynamics, UNITED
Rosanna Peeling, Professor & Chair of Diagnostics Research, London School of Hygiene & Tropical Medicines, UK
Teri Roberts, Diagnostics Advisor (HIV and Hepatitis), MSF
David Rippin, Clinton Health Access Initiative, USA
Ben Plumley, CEO, Pangaea Global AIDS Foundation, USA
Monday, July 1st
12:30pm-2:30pm; Exhibition Hall, Ground Level
Factors Associated with gender-based violence and unintended pregnancy among Adolescent Women Living with HIV in Zimbabwe
D. Nhamo, I. Mudekunye - Mahaka, O.Chang, A.Chingono, G. Kadzirange, M. Dunbar
Factors associated with CD4>=350 and/or being on ART among adolescent women living with HIV in Zimbabwe
M. Dunbar, O. Chang, I. Mudekunye-Mahaka, D. Nhamo, G. Kadzirange
Tuesday, July 2nd
12:30pm-2:30pm; Exhibition Hall, Ground Level
Delivery of Methadone Treatment in Dar es Salaam, Tanzania: Feasibility, Retention and Early Outcomes
B. Lambdin, D. Bruce, O. Chang, F. Masao, C. Nyandindi, N. Sabuni, E. Matiko, K. Kazaura, S. Mccurdy, J. Mbwambo
Pangaea Global AIDS Foundation Observes National Youth HIV + AIDS Awareness Day
National Youth HIV + AIDS Awareness Day (NYHAAD) is a community mobilization initiative designed to raise awareness of HIV/AIDS prevention, testing, care and treatment among youth ages 12 to 25 in the United States.
This campaign has four main objectives:
· Education: Distribute information about HIV/AIDS
· Testing: Establish April 10th as an annual day for youth to get an HIV test
· Involvement: Increase the number of youth involved in prevention campaigns and mobilizes communities around HIV/AIDS
· Treatment: Raise awareness of treatment services and information for HIV+ youth
When is NYHAAD recognized?
April 10, 2013, this is
the first year of its observance.
Why is an awareness day needed?
About 1 in 4 (26%) of all new HIV infections occur among youth between the ages of 13 and 24 years. About 60% of youth living with HIV do not know they are infected and therefore don’t receive treatment. This puts them at risk for sickness and early death. These youth can also unknowingly pass HIV to others.
Who are the organizers?
NYHAAD is a national initiative of the project Advocates For Youth. Advocates for Youth champions efforts to help young people make informed and responsible decisions about their reproductive and sexual health. Advocates For Youth believes it can best serve the field by boldly advocating for a more positive and realistic approach to adolescent sexual health.
Advocates For Youth envision a society that views sexuality as normal and healthy and treats young people as a valuable resource. The core values of Rights, Respect, and Responsibility® (3Rs) animate this vision:
Youth have rights to accurate and complete sexual health information, confidential reproductive and sexual health services, and a secure stake in the future.
Youth deserve respect. Today, young people are largely perceived as part of the problem. Valuing young people means they are part of the solution and are included in developing programs and policies that affect their well-being.
Society has the responsibility to provide young people with the tools they need to safeguard their sexual health. In turn, young people have the responsibility to protect themselves from too-early childbearing and sexually transmitted infections (STIs), including HIV.